Nwam LLC Grows Holdings in Merck & Company, Inc. (MRK)

Nwam LLC raised its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 15.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,847 shares of the company’s stock after purchasing an additional 1,824 shares during the period. Nwam LLC’s holdings in Merck & were worth $887,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vigilant Capital Management LLC increased its stake in shares of Merck & by 16.7% in the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. increased its stake in shares of Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the last quarter. Harbour Capital Advisors LLC bought a new stake in shares of Merck & in the 1st quarter valued at about $127,000. Mascoma Wealth Management LLC increased its stake in shares of Merck & by 8.2% in the 2nd quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock valued at $159,000 after acquiring an additional 187 shares during the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Merck & by 17.5% in the 2nd quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock valued at $174,000 after acquiring an additional 404 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

MRK has been the subject of a number of recent analyst reports. UBS AG upped their price target on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on Merck & and gave the company a “buy” rating in a research note on Saturday, July 29th. BMO Capital Markets reaffirmed a “buy” rating and issued a $74.00 price target on shares of Merck & in a research note on Tuesday, June 27th. Credit Suisse Group reaffirmed a “buy” rating on shares of Merck & in a research note on Tuesday, June 13th. Finally, BidaskClub raised Merck & from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Merck & has an average rating of “Hold” and a consensus price target of $69.81.

Shares of Merck & Company, Inc. (NYSE MRK) opened at 64.46 on Wednesday. Merck & Company, Inc. has a 1-year low of $58.29 and a 1-year high of $66.80. The company has a market capitalization of $175.81 billion, a PE ratio of 34.90 and a beta of 0.80. The company’s 50-day moving average price is $64.42 and its 200-day moving average price is $63.70.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. During the same period in the previous year, the firm earned $0.93 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. On average, equities analysts expect that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 6th. Shareholders of record on Friday, September 15th were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend was Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.

COPYRIGHT VIOLATION WARNING: “Nwam LLC Grows Holdings in Merck & Company, Inc. (MRK)” was reported by The Ledger Gazette and i

Other institutional investors have also added to or reduced their stakes in the company. Vigilant Capital Management LLC increased its stake in shares of Merck & by 16.7% in the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. increased its stake in shares of Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the last quarter. Harbour Capital Advisors LLC bought a new stake in shares of Merck & in the 1st quarter valued at about $127,000. Mascoma Wealth Management LLC increased its stake in shares of Merck & by 8.2% in the 2nd quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock valued at $159,000 after acquiring an additional 187 shares during the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Merck & by 17.5% in the 2nd quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock valued at $174,000 after acquiring an additional 404 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

MRK has been the subject of a number of recent analyst reports. UBS AG upped their price target on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on Merck & and gave the company a “buy” rating in a research note on Saturday, July 29th. BMO Capital Markets reaffirmed a “buy” rating and issued a $74.00 price target on shares of Merck & in a research note on Tuesday, June 27th. Credit Suisse Group reaffirmed a “buy” rating on shares of Merck & in a research note on Tuesday, June 13th. Finally, BidaskClub raised Merck & from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Merck & has an average rating of “Hold” and a consensus price target of $69.81.

Shares of Merck & Company, Inc. (NYSE MRK) opened at 64.46 on Wednesday. Merck & Company, Inc. has a 1-year low of $58.29 and a 1-year high of $66.80. The company has a market capitalization of $175.81 billion, a PE ratio of 34.90 and a beta of 0.80. The company’s 50-day moving average price is $64.42 and its 200-day moving average price is $63.70.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. During the same period in the previous year, the firm earned $0.93 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. On average, equities analysts expect that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 6th. Shareholders of record on Friday, September 15th were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend was Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.

COPYRIGHT VIOLATION WARNING: “Nwam LLC Grows Holdings in Merck & Company, Inc. (MRK)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/11/nwam-llc-grows-holdings-in-merck-company-inc-mrk.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply